Supernus Pharmaceuticals Net Worth 2012-2026 | SUPN

Interactive chart of historical net worth (market cap) for Supernus Pharmaceuticals (SUPN) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Supernus Pharmaceuticals net worth as of June 18, 2026 is $2.92B.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.918B $0.719B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $35.437B 10.97
BridgeBio Pharma (BBIO) United States $14.460B 0.00
Dr Reddy's Laboratories (RDY) India $11.109B 17.29
Aspen Pharmacare (APNHY) South Africa $3.708B 0.00
Bausch Health Cos (BHC) Canada $2.086B 1.50
Taysha Gene Therapies (TSHA) United States $1.290B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.924B 7.28
Personalis (PSNL) United States $0.630B 0.00
Assembly Biosciences (ASMB) United States $0.451B 0.00
Sol-Gel Technologies (SLGL) Israel $0.210B 0.00
Metagenomi Therapeutics (MGX) United States $0.052B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00